Cultured epidermal autograft in the treatment of leukoderma, refractory scar and refractory skin ulcer.

Efficacy of cultured epidermal autograft in the treatment of vitiligo, refractory scar and refractory skin ulcer. - Efficacy of cultured epidermal autograft for skin disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTb040190122

Enrollment

Registered

2020-03-02

Start date

2017-08-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo, refractory scar and refractory skin ulcer

Interventions

1) Taking healthy skin 2) Skin lesion is erased 3) Cultured epidermal autograft

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) The person who has vitiligo, refractory scar and refractory skin ulcer more than six months (2) The person who understand and consent this clinical trial. The necessity of written consent by legal representatives (parents, guardians) as well as by the principal when the person is restricted in the age (from 16 to 20). Additionally, The necessity of written consent by legal representatives (parents, guardians) when the person is under 16 year od age. (3) Negative in the prescribed infection inspection (hepatitis B, hepatitis C, syphilis, human immunodeficincy virus, adult T cell leukemia)

Exclusion criteria

Exclusion criteria: (1) Allergy to antibiotic (penicillin, kanamycin, streptomycin, amphotericin B), medical history of allergy to penicillins and aminoglycoside. (2) Allergy to animals (cow, mouse, pig) (3) Suspected , present illness and medical history of skin malignant tumor (4) Difficulty of participation due to mental disorder (5) Pregnant, lactating woman and possibility of pregnancy (6) Skin Infectious disease requiring systemic medical treatment (7) Positive in the prescribed infection inspection (hepatitis B, hepatitis C, syphilis, human immunodeficincy virus, adult T cell leukemia) (8) Not suitable for this clinical trial from the view oint of the doctors who perform regenerative medicine

Design outcomes

Primary

Measure	Time frame
Rate of efficiency of improvement of diseases. The degree of efficiency is estimated by image analyses at the one of the following: extremely effective (100 - 70 %), effective (70- 50 %), slightly effective (50- 10 %), poorly effective (10- 0 %), uneffecive (0 %).	—

Secondary

Measure	Time frame
Quantitative evaluation 1) Spectral colorimeter, 2) skin viscoelasticity	—

Countries

Japan

Contacts

Public ContactSanae Ito

Nagoya City University

ncu_sai@med.nagoya-cu.ac.jp+81-52-853-8348

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026